Purpose: To evaluate control of intraocular pressure (IOP) and IOP fluctuation in patients with ocular hypertension or glaucoma treated with fixed-combination brimonidine-timolol compared with brimonidine or timolol monotherapy.

Design: Post hoc analysis of data from 2 identical, 12-month, randomized, double-masked, multicenter trials.

Methods: Patients were treated bilaterally with fixed brimonidine-timolol twice a day (n = 385), brimonidine tartrate 0.2% 3 times a day (n = 382), or timolol 0.5% twice a day (n = 392). Diurnal IOP was measured at follow-up visits at weeks 2 and 6 and months 3, 6, 9, and 12. IOP fluctuation was defined as the standard deviation of IOP measurements.

Results: The percentage of patients with mean diurnal IOP <18 mm Hg and short-term (daily) IOP fluctuation ≤2 mm Hg was statistically significantly higher in the brimonidine-timolol group than in the brimonidine or timolol group at each follow-up visit (at month 12, brimonidine-timolol 43.0%; brimonidine 18.9%, timolol 33.5%, P ≤ .017). At each hour (8 AM, 10 AM, 3 PM, and 5 PM), the percentage of patients with mean IOP <18 mm Hg and long-term (intervisit) IOP fluctuation ≤2 mm Hg was statistically significantly higher with brimonidine-timolol than with brimonidine or timolol alone (at 8 AM, brimonidine-timolol 41.0%, brimonidine 11.3%, timolol 23.7%, P < .001).

Conclusions: Patients treated with fixed-combination brimonidine-timolol were more likely than patients treated with either brimonidine or timolol alone to achieve a combination of low mean IOP and low short-term (daily) or long-term (intervisit) IOP fluctuation.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2010.07.024DOI Listing

Publication Analysis

Top Keywords

control intraocular
8
intraocular pressure
8
fixed-combination brimonidine-timolol
8
brimonidine timolol
8
iop fluctuation
8
diurnal iop
8
iop
6
pressure fluctuation
4
fluctuation fixed-combination
4
brimonidine-timolol versus
4

Similar Publications

Purpose: Scleral cross-linking (SXL) with ultraviolet A (UVA) and riboflavin has already been used in laboratory studies for scleral stiffness increase as a potential treatment for progressive myopia and scleral ectasia. This study aims to investigate whether the regional application of scleral cross-linking (SXL) with ultraviolet A (UVA) and riboflavin in fresh porcine eye globes affects the ocular rigidity as well as its impact on intraocular pressure after an induced acute increase in the volume of intraocular fluid.

Methods: The study included two groups of fresh porcine eyes: an experimental group (n=20) that underwent scleral cross-linking (SXL) with riboflavin and UVA applied to the posterior sclera and a control group (n=20) that did not receive SXL treatment.

View Article and Find Full Text PDF

: This study aimed to assess the role of macular pigment optical density (MPOD) in patients with a full-thickness macular hole (FTMH) compared to healthy controls, evaluating postoperative changes in MPOD and exploring potential correlations with visual outcomes. : This prospective, cross-sectional, comparative study included 16 eyes from FTMH patients who achieved anatomical hole closure following pars plana vitrectomy with the inverted ILM flap technique. Each eye underwent a comprehensive ophthalmologic examination, including BCVA and intraocular pressure measurements, anterior segment evaluation, fundus examination, and macular assessment with Enhanced Depth Imaging Optical Coherence Tomography (EDI-OCT, Spectralis, Heidelberg Engineering Inc.

View Article and Find Full Text PDF

Prcis: Community-based eye health screenings that incorporated fundus photography and optometric exams in a high-risk NYC population effectively identified a higher than average number of participants that required an in-office glaucoma evaluation.

Purpose: To report glaucoma screening rates and risk factors associated with referral for in-office glaucoma evaluation in the Manhattan Vision Screening and Follow-up Study (NYC-SIGHT).

Methods: In this 5-year, cluster-randomized clinical trial, eligible individuals aged 40 and older were recruited from affordable housing developments and senior centers.

View Article and Find Full Text PDF

Treatment of pseudophakic aqueous misdirection syndrome.

Sci Rep

January 2025

Department of Ophthalmology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland.

To describe the management and clinical course of 12 cases of pseudophakic aqueous misdirection syndrome (AMS). Twelve eyes of 12 Patients diagnosed with pseudophakic AMS between 2021 and 2022 were included. Best-corrected visual acuity, refraction, intraocular pressure (IOP), anti-glaucomatous medication, spectral domain ocular coherence tomography (SD-OCT) and postoperative complications were evaluated.

View Article and Find Full Text PDF

A retrospective study on ruthenium-106 and strontium-90 eye-plaques treatment for retinoblastoma: 16-years clinical experience.

Brachytherapy

January 2025

Ocular Oncology and Radiology Department, S. Fyodorov Eye Microsurgery Federal State Institution, Moscow, Russia.

Purpose: To retrospectively evaluate the efficacy of plaque brachytherapy for the treatment of retinoblastoma.

Methods: We retrospectively reviewed the clinical records of 163 patients (186 eyes, 333 tumors) treated with brachytherapy (Ru or Sr plaques) for intraocular retinoblastoma between November 2007 and August 2023.

Results: Complete tumor control was achieved in 273 tumors (82%).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!